ketanserin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Ketanserin (INN, USAN, BAN) (brand name Sufrexal; former developmental code name R41468) is a drug used clinically as an antihypertensive agent and in scientific research to study the serotonergic system; specifically, the 5-HT2 receptor family. It was discovered at Janssen Pharmaceutica in 1980. It is not available in the United States.   Wikipedia

Chemistry

  • SMILES: Fc1ccc(cc1)C(=O)C2CCN(CCN3C(=O)Nc4ccccc4C3=O)CC2
  • InChIKey: FPCCSQOGAWCVBH-UHFFFAOYSA-N
  • Mol. Mass: 395.43
  • ALogP: 2.42
  • ChEMBL Molecules:
    ketanserin  
    ketanserin tartrate  
More Chemistry

Pharmacology

Alternative names

ketanserin | ketanserin tartrate | ketanserin tartrate hydrate | ketensin | r 41468 | r 41 468 | r-41468 | suffrexal | sufrexal

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Acute Kidney Injury (Phase 3)

Critical Illness (Phase 4)

Depressive Disorder, Major (Phase 2)

Diabetic Foot (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Sepsis (Phase 3)

Shock, Septic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue